UNSPSC 51173228: Docusate/sennosides

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA204. This VA Drug Class (GA204) classifies this compound as belonging to the group STIMULANT LAXATIVES.

UNSPSC 51173228 Docusate/sennosides is a Commodity code representing specific laxative and stool-softening pharmaceutical products that state and local governments procure primarily through pharmacy benefit programs, cooperative purchasing alliances, and correctional health systems. Recent solicitation activity shows state and local buyers acquiring these products as components of broader pharmaceutical supply contracts rather than as standalone line items, with actual purchasing embedded within multi-source generic drug procurement frameworks and offender health services platforms.

Activity under the code clusters in Texas and the Upper Midwest. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription fulfillment models, signaling the state's intent to refactor how it sources pharmaceuticals including generics. Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026, estimated contract value $600,000) represents the more specialized use case—correctional systems procuring health services where docusate and sennosides would be ancillary pharmacy components. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 (due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson). The MMCAP solicitation emphasizes price competitiveness (75 percent of evaluation weight), cGMP and DSCSA compliance, EDI capability, and flexible net-pricing models—standard procurement architecture for commodity generics in which docusate and sennosides would be listed SKUs.